AngioDynamics (NSDQ:ANGO) said it won CE Mark approval in the European Union for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit.
The device is designed for use during extracorporeal bypass for up to 6 hours. Under the CE Mark approval, the AngioVac cannula is also approved for removal of fresh, soft thrombi or emboli.
"The AngioVac cannula and circuit have shown great promise in improving patient outcomes and reducing the cost of treatment when dealing with the removal of soft thrombus," John Soto, senior vice president of AngioDynamics’ global peripheral vascular franchise, said in prepared remarks. "CE Mark approval makes this powerful tool available to physicians across the EU."
Last month AngioDynamics won a nod north of the border for its Celerity PICC tip locating device. Earlier this month, the company closed the books on a 3-year-old distribution spat with Cardinal Health, with the companies agreeing to a terminate the lawsuit late last month.
